Weight loss outcomes with FDA-approved medications

Weight loss reflects results at 52 weeks, except for semaglutide and liraglutide, which reflect weight loss at 68 weeks.

FDA: US Food and Drug Administration.

Courtesy of George A Bray, MD.
Data from:

Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016; 315:2424.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022; 327:138.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.

Graphic 115096 Version 5.0